Production of functional, stable, unmutated recombinant human papillomavirus E6 oncoprotein

Implications for HPV-tumor diagnosis and therapy

Elena Illiano, Olivia Costantina Demurtas, Silvia Massa, Paola Bonito, Valerio Consalvi, Roberta Chiaraluce, Carlo Zanotto, Carlo Giuli Morghen, Antonia Radaelli, Aldo Venuti, Rosella Franconi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: High-risk human papillomaviruses (HR-HPVs) types 16 and 18 are the main etiological agents of cervical cancer, with more than 550,000 new cases each year worldwide. HPVs are also associated with other ano-genital and head-and-neck tumors. The HR-HPV E6 and E7 oncoproteins are responsible for onset and maintenance of the cell transformation state, and they represent appropriate targets for development of diagnostic and therapeutic tools. Methods: The unmutated E6 gene from HPV16 and HPV18 and from low-risk HPV11 was cloned in a prokaryotic expression vector for expression of the Histidine-tagged E6 protein (His6-E6), according to a novel procedure. The structural properties were determined using circular dichroism and fluorescence spectroscopy. His6-E6 oncoprotein immunogenicity was assessed in a mouse model, and its functionality was determined using in vitro GST pull-down and protein degradation assays. Results: The His6-tagged E6 proteins from HPV16, HPV18, and HPV11 E6 genes, without any further modification in the amino-acid sequence, were produced in bacteria as soluble and stable molecules. Structural analyses of HPV16 His6-E6 suggests that it maintains correct folding and conformational properties. C57BL/6 mice immunized with HPV16 His6-E6 developed significant humoral immune responses. The E6 proteins from HPV16, HPV18, and HPV11 were purified according to a new procedure, and investigated for protein-protein interactions. HR-HPV His6-E6 bound p53, the PDZ1 motif from MAGI-1 proteins, the human discs large tumor suppressor, and the human ubiquitin ligase E6-associated protein, thus suggesting that it is biologically active. The purified HR-HPV E6 proteins also targeted the MAGI-3 and p53 proteins for degradation. Conclusions: This new procedure generates a stable, unmutated HPV16 E6 protein, which maintains the E6 properties in in vitro binding assays. This will be useful for basic studies, and for development of diagnostic kits and immunotherapies in preclinical mouse models of HPV-related tumorigenesis.

Original languageEnglish
Article number224
JournalJournal of Translational Medicine
Volume14
Issue number1
DOIs
Publication statusPublished - Jul 28 2016

Fingerprint

Oncogene Proteins
Tumors
Neoplasms
Proteins
Proteolysis
Therapeutics
Human papillomavirus 18
Human papillomavirus 16
Fluorescence Spectrometry
Ligases
Humoral Immunity
Circular Dichroism
Ubiquitin
Assays
Inbred C57BL Mouse
Histidine
Uterine Cervical Neoplasms
Immunotherapy
Genes
Amino Acid Sequence

Keywords

  • Biomarker
  • Diagnostic
  • E6 oncoprotein
  • HPV
  • Vaccines

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Production of functional, stable, unmutated recombinant human papillomavirus E6 oncoprotein : Implications for HPV-tumor diagnosis and therapy. / Illiano, Elena; Demurtas, Olivia Costantina; Massa, Silvia; Bonito, Paola; Consalvi, Valerio; Chiaraluce, Roberta; Zanotto, Carlo; Giuli Morghen, Carlo; Radaelli, Antonia; Venuti, Aldo; Franconi, Rosella.

In: Journal of Translational Medicine, Vol. 14, No. 1, 224, 28.07.2016.

Research output: Contribution to journalArticle

Illiano, E, Demurtas, OC, Massa, S, Bonito, P, Consalvi, V, Chiaraluce, R, Zanotto, C, Giuli Morghen, C, Radaelli, A, Venuti, A & Franconi, R 2016, 'Production of functional, stable, unmutated recombinant human papillomavirus E6 oncoprotein: Implications for HPV-tumor diagnosis and therapy', Journal of Translational Medicine, vol. 14, no. 1, 224. https://doi.org/10.1186/s12967-016-0978-6
Illiano, Elena ; Demurtas, Olivia Costantina ; Massa, Silvia ; Bonito, Paola ; Consalvi, Valerio ; Chiaraluce, Roberta ; Zanotto, Carlo ; Giuli Morghen, Carlo ; Radaelli, Antonia ; Venuti, Aldo ; Franconi, Rosella. / Production of functional, stable, unmutated recombinant human papillomavirus E6 oncoprotein : Implications for HPV-tumor diagnosis and therapy. In: Journal of Translational Medicine. 2016 ; Vol. 14, No. 1.
@article{c1d97d0fc5ec4005b10c6f426c71a66c,
title = "Production of functional, stable, unmutated recombinant human papillomavirus E6 oncoprotein: Implications for HPV-tumor diagnosis and therapy",
abstract = "Background: High-risk human papillomaviruses (HR-HPVs) types 16 and 18 are the main etiological agents of cervical cancer, with more than 550,000 new cases each year worldwide. HPVs are also associated with other ano-genital and head-and-neck tumors. The HR-HPV E6 and E7 oncoproteins are responsible for onset and maintenance of the cell transformation state, and they represent appropriate targets for development of diagnostic and therapeutic tools. Methods: The unmutated E6 gene from HPV16 and HPV18 and from low-risk HPV11 was cloned in a prokaryotic expression vector for expression of the Histidine-tagged E6 protein (His6-E6), according to a novel procedure. The structural properties were determined using circular dichroism and fluorescence spectroscopy. His6-E6 oncoprotein immunogenicity was assessed in a mouse model, and its functionality was determined using in vitro GST pull-down and protein degradation assays. Results: The His6-tagged E6 proteins from HPV16, HPV18, and HPV11 E6 genes, without any further modification in the amino-acid sequence, were produced in bacteria as soluble and stable molecules. Structural analyses of HPV16 His6-E6 suggests that it maintains correct folding and conformational properties. C57BL/6 mice immunized with HPV16 His6-E6 developed significant humoral immune responses. The E6 proteins from HPV16, HPV18, and HPV11 were purified according to a new procedure, and investigated for protein-protein interactions. HR-HPV His6-E6 bound p53, the PDZ1 motif from MAGI-1 proteins, the human discs large tumor suppressor, and the human ubiquitin ligase E6-associated protein, thus suggesting that it is biologically active. The purified HR-HPV E6 proteins also targeted the MAGI-3 and p53 proteins for degradation. Conclusions: This new procedure generates a stable, unmutated HPV16 E6 protein, which maintains the E6 properties in in vitro binding assays. This will be useful for basic studies, and for development of diagnostic kits and immunotherapies in preclinical mouse models of HPV-related tumorigenesis.",
keywords = "Biomarker, Diagnostic, E6 oncoprotein, HPV, Vaccines",
author = "Elena Illiano and Demurtas, {Olivia Costantina} and Silvia Massa and Paola Bonito and Valerio Consalvi and Roberta Chiaraluce and Carlo Zanotto and {Giuli Morghen}, Carlo and Antonia Radaelli and Aldo Venuti and Rosella Franconi",
year = "2016",
month = "7",
day = "28",
doi = "10.1186/s12967-016-0978-6",
language = "English",
volume = "14",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Production of functional, stable, unmutated recombinant human papillomavirus E6 oncoprotein

T2 - Implications for HPV-tumor diagnosis and therapy

AU - Illiano, Elena

AU - Demurtas, Olivia Costantina

AU - Massa, Silvia

AU - Bonito, Paola

AU - Consalvi, Valerio

AU - Chiaraluce, Roberta

AU - Zanotto, Carlo

AU - Giuli Morghen, Carlo

AU - Radaelli, Antonia

AU - Venuti, Aldo

AU - Franconi, Rosella

PY - 2016/7/28

Y1 - 2016/7/28

N2 - Background: High-risk human papillomaviruses (HR-HPVs) types 16 and 18 are the main etiological agents of cervical cancer, with more than 550,000 new cases each year worldwide. HPVs are also associated with other ano-genital and head-and-neck tumors. The HR-HPV E6 and E7 oncoproteins are responsible for onset and maintenance of the cell transformation state, and they represent appropriate targets for development of diagnostic and therapeutic tools. Methods: The unmutated E6 gene from HPV16 and HPV18 and from low-risk HPV11 was cloned in a prokaryotic expression vector for expression of the Histidine-tagged E6 protein (His6-E6), according to a novel procedure. The structural properties were determined using circular dichroism and fluorescence spectroscopy. His6-E6 oncoprotein immunogenicity was assessed in a mouse model, and its functionality was determined using in vitro GST pull-down and protein degradation assays. Results: The His6-tagged E6 proteins from HPV16, HPV18, and HPV11 E6 genes, without any further modification in the amino-acid sequence, were produced in bacteria as soluble and stable molecules. Structural analyses of HPV16 His6-E6 suggests that it maintains correct folding and conformational properties. C57BL/6 mice immunized with HPV16 His6-E6 developed significant humoral immune responses. The E6 proteins from HPV16, HPV18, and HPV11 were purified according to a new procedure, and investigated for protein-protein interactions. HR-HPV His6-E6 bound p53, the PDZ1 motif from MAGI-1 proteins, the human discs large tumor suppressor, and the human ubiquitin ligase E6-associated protein, thus suggesting that it is biologically active. The purified HR-HPV E6 proteins also targeted the MAGI-3 and p53 proteins for degradation. Conclusions: This new procedure generates a stable, unmutated HPV16 E6 protein, which maintains the E6 properties in in vitro binding assays. This will be useful for basic studies, and for development of diagnostic kits and immunotherapies in preclinical mouse models of HPV-related tumorigenesis.

AB - Background: High-risk human papillomaviruses (HR-HPVs) types 16 and 18 are the main etiological agents of cervical cancer, with more than 550,000 new cases each year worldwide. HPVs are also associated with other ano-genital and head-and-neck tumors. The HR-HPV E6 and E7 oncoproteins are responsible for onset and maintenance of the cell transformation state, and they represent appropriate targets for development of diagnostic and therapeutic tools. Methods: The unmutated E6 gene from HPV16 and HPV18 and from low-risk HPV11 was cloned in a prokaryotic expression vector for expression of the Histidine-tagged E6 protein (His6-E6), according to a novel procedure. The structural properties were determined using circular dichroism and fluorescence spectroscopy. His6-E6 oncoprotein immunogenicity was assessed in a mouse model, and its functionality was determined using in vitro GST pull-down and protein degradation assays. Results: The His6-tagged E6 proteins from HPV16, HPV18, and HPV11 E6 genes, without any further modification in the amino-acid sequence, were produced in bacteria as soluble and stable molecules. Structural analyses of HPV16 His6-E6 suggests that it maintains correct folding and conformational properties. C57BL/6 mice immunized with HPV16 His6-E6 developed significant humoral immune responses. The E6 proteins from HPV16, HPV18, and HPV11 were purified according to a new procedure, and investigated for protein-protein interactions. HR-HPV His6-E6 bound p53, the PDZ1 motif from MAGI-1 proteins, the human discs large tumor suppressor, and the human ubiquitin ligase E6-associated protein, thus suggesting that it is biologically active. The purified HR-HPV E6 proteins also targeted the MAGI-3 and p53 proteins for degradation. Conclusions: This new procedure generates a stable, unmutated HPV16 E6 protein, which maintains the E6 properties in in vitro binding assays. This will be useful for basic studies, and for development of diagnostic kits and immunotherapies in preclinical mouse models of HPV-related tumorigenesis.

KW - Biomarker

KW - Diagnostic

KW - E6 oncoprotein

KW - HPV

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=84979590897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979590897&partnerID=8YFLogxK

U2 - 10.1186/s12967-016-0978-6

DO - 10.1186/s12967-016-0978-6

M3 - Article

VL - 14

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 224

ER -